Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHYF) Enterprise Value (2017 - 2025)

Historic Enterprise Value for Innate Pharma (IPHYF) over the last 9 years, with Q2 2025 value amounting to -$82.3 million.

  • Innate Pharma's Enterprise Value rose 1728.76% to -$82.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$82.3 million, marking a year-over-year increase of 1728.76%. This contributed to the annual value of -$86.3 million for FY2024, which is 1323.59% up from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Enterprise Value is -$82.3 million, which was up 1728.76% from -$86.3 million recorded in Q4 2024.
  • Innate Pharma's 5-year Enterprise Value high stood at -$82.3 million for Q2 2025, and its period low was -$183.2 million during Q2 2021.
  • In the last 5 years, Innate Pharma's Enterprise Value had a median value of -$103.5 million in 2022 and averaged -$115.0 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first surged by 9987.6% in 2021, then surged by 392.38% in 2023.
  • Innate Pharma's Enterprise Value (Quarter) stood at -$137.1 million in 2021, then grew by 24.47% to -$103.5 million in 2022, then grew by 3.92% to -$99.5 million in 2023, then increased by 13.24% to -$86.3 million in 2024, then rose by 4.63% to -$82.3 million in 2025.
  • Its Enterprise Value was -$82.3 million in Q2 2025, compared to -$86.3 million in Q4 2024 and -$99.5 million in Q2 2024.